July 20, 2026
1 min read

Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide

South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs ($1.8 billion).

Leave a Reply

Your email address will not be published.

Previous Story

USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada, Deepening Commitment to Clean Sport and Elite Athlete Nutrition

Next Story

Plant-based whole food proteins blunt post-workout muscle synthesis, study finds

Previous Story

USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada, Deepening Commitment to Clean Sport and Elite Athlete Nutrition

Next Story

Plant-based whole food proteins blunt post-workout muscle synthesis, study finds

Latest from Blog

Go toTop